- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00787332
A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome (HIT)
January 6, 2013 updated by: Canyon Pharmaceuticals, Inc.
A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS)
Compare Clinical Success and Costs in two Arms
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Demonstrate clinical and economic utility between the study Arms.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Health Science Center
-
-
District of Columbia
-
Washington, DC, District of Columbia, United States, 20010
- Washington Regional Cardiac Surgery
-
-
Florida
-
Orlando, Florida, United States, 32801
- Florida Hospital Cardiovascular Research
-
Tampa, Florida, United States, 33606
- University of South Florida, Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory University, Emory Crawford Long Hospital
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96819
- Kaiser Permanente Medical Center
-
-
Illinois
-
Joliet, Illinois, United States, 60435
- Provena St. Joseph's Medical Center
-
-
Iowa
-
Sioux City, Iowa, United States, 51101
- Mercy Medical Center
-
-
Maine
-
Portland, Maine, United States, 04102
- Maine Medical Center
-
-
Michigan
-
Royal Oak, Michigan, United States, 48073
- William Beaumont Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- St Mary's Hospital Rochester, Mayo Clinic
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- UMDNJ-Robert Wood Johnson Medical School
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center, Moses Division
-
Manhasset, New York, United States, 11030
- North Shore University Hospital
-
Manhattan, New York, United States, 10011
- St Vincent's Hosptial -Manhattan
-
New York, New York, United States, 10029
- Mount Sinai Clinical & Translational Research Institute
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 55902
- Forsyth Regional Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- The Cleveland Clinic
-
Columbus, Ohio, United States, 43210
- The Ohio State University Medical Center
-
Columbus, Ohio, United States, 42314
- Cardiothoracic Vascular Surgial Specialists
-
-
Texas
-
Houston, Texas, United States, 77030
- Methodist Hospital
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah Hospital
-
-
West Virginia
-
Charleston, West Virginia, United States, 25304
- Charleston Area Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provide written Informed Consent
- Be at least 18 years of age.
A suspicion of heparin-induced thrombocytopenia with or without thrombosis syndrome (HIT/TS) due to one of the following clinical scenarios:
Patients who are receiving heparin/LMWH or have received heparin/LMWH within the previous 100 days AND one of the following:
- have a fall in platelet count of > 30% from a baseline prior to heparin/LMWH, OR
- have a thrombotic event, OR
- develop skin lesions secondary to subcutaneous heparin (even if the patient is no longer receiving heparin therapy when thrombocytopenia, thrombosis or skin lesions occur).
Patients with thrombosis or skin lesions need not have concomitant thrombocytopenia to be included.
- A rapid fall in the platelet count by >30% from baseline within 24 hours after starting heparin/LMWH in patients with suspected exposure to heparin or LMWH in the previous 100 days (e.g. hospitalization or invasive procedure within the past 100 days).
- In post-operative cardiac surgery patients, development of thrombocytopenia defined as a decrease in platelet count by >30% from the post-operative peak; or patients whose platelet count fails to increase post-operatively (e.g. remains < 100,000 mm3 at Day 4 or later, calendar day of surgery=Day 0).
- In patients with the diagnosis of HIT/TS established by a hematology consultant, but in whom the above criteria are not fulfilled, the Investigator should contact the Medical Monitor for consideration of the patient's inclusion in this study (A hematology consult is highly advisable, but not required prior to randomization).
Exclusion Criteria:
- Confirmed pregnancy (if woman of child-bearing potential- urine or serum pregnancy test).
- Patients with suspected or confirmed pulmonary embolism, requiring continued anticoagulation or acute ischemic stroke will be excluded
- Cerebrovascular accident within the previous 6 months
- Intracranial neoplasm, arteriovenous malformation or aneurysm.
- Severe renal insufficiency as determined by measured or estimated creatinine clearance < 30 ml/min.
- Known allergy to Argatroban®, Desirudin or hirudin derived drugs, or known sensitivity to any component of the product
- Patients receiving recombinant hirudin (e.g. lepirudin) within the previous 6 months prior to enrollment.
- Patients receiving >2 doses of fondaparinux for treatment of suspected HIT
- Multi-system organ failure or estimated survival of less than 30 days.
- Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment
- Refusal to undergo blood transfusion should it become necessary
- Active bleeding or irreversible coagulation abnormality
- Uncontrolled hypertension defined as a blood pressure >180/110 mm Hg.
- Patients requiring indwelling mechanical intervention such as left-ventricular assist device, intra-aortic balloon pump, veno-venous ultra filtration, etc.
- Severe liver disease and any other disease or condition, which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Desirudin
Patients with suspected HIT without thrombosis syndrome (HIT/TS), randomized to SC Desirudin
|
Desirudin 15mg SC Argatroban® IV dosing per Package Insert
|
ACTIVE_COMPARATOR: Argatroban®
Patients randomized to IV Argatroban®
|
Desirudin 15mg SC Argatroban® IV dosing per Package Insert
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
New Thrombosis, Amputation, Death, Major and Minor Bleeding
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Boyce SW, Bandyk DF, Bartholomew JR, Frame JN, Rice L. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study. Am J Ther. 2011 Jan;18(1):14-22. doi: 10.1097/MJT.0b013e3181f65503.
- Frame JN, Rice L, Bartholomew JR, Whelton A. Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. Clin Ther. 2010 Apr;32(4):626-36. doi: 10.1016/j.clinthera.2010.04.012.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2008
Primary Completion (ACTUAL)
December 1, 2009
Study Completion (ACTUAL)
December 1, 2009
Study Registration Dates
First Submitted
November 6, 2008
First Submitted That Met QC Criteria
November 6, 2008
First Posted (ESTIMATE)
November 7, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
January 10, 2013
Last Update Submitted That Met QC Criteria
January 6, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hematologic Diseases
- Embolism and Thrombosis
- Blood Platelet Disorders
- Thrombosis
- Thrombocytopenia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Protease Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Argatroban
- Desirudin
Other Study ID Numbers
- DES-08-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Suspected Heparin-Induced Thrombocytopenia
-
Central Hospital, Nancy, FranceRecruitingHeparin-induced ThrombocytopeniaFrance
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingHeparin-induced Thrombocytopenia
-
University of ArizonaAmerican College of Clinical PharmacyRecruitingHeparin-induced ThrombocytopeniaUnited States
-
Veralox TherapeuticsCelerionCompletedHeparin-induced ThrombocytopeniaUnited States
-
Aspen Global IncorporatedTerminatedHeparin-induced ThrombocytopeniaUnited States, Bosnia and Herzegovina, Canada, France, Germany, Italy, Poland, Russian Federation, Serbia
-
Marshall UniversityUnknownHeparin-induced ThrombocytopeniaUnited States
-
Ottawa Hospital Research InstituteUnknownHeparin-induced Thrombocytopenia (HIT)Canada
-
Vanderbilt University Medical CenterAmerican Heart AssociationCompletedHeparin-induced ThrombocytopeniaUnited States
-
Central Hospital, Nancy, FranceCompletedHeparin-induced Thrombocytopenia
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)CompletedHeparin Induced ThrombocytopeniaUnited States
Clinical Trials on Desirudin or Argatroban®
-
Universitair Ziekenhuis BrusselUnknown
-
Methodist HealthcareUniversity of TennesseeWithdrawnHeparin-Induced Thrombocytopenia
-
Labo'LifeRecruitingPlantar Wart | Common Wart | Flat WartBelgium
-
University Hospital, BonnActive, not recruitingDepression | HealthyGermany
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationCompletedKidney Failure, AcuteSwitzerland, Italy
-
Asan Medical CenterCompletedQuality of Life | Breast CancerKorea, Republic of
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Gedeon Richter Plc.CompletedBioequivalenceUnited Kingdom
-
Center Eugene MarquisActive, not recruitingSolid Tumor, Adult | Chemotherapy Treatment | Advanced or Metastasis StageFrance
-
Cook Research IncorporatedCompletedAortic Aneurysm, AbdominalUnited States